Evidence map›Paper›PMID 39083160›Full record

ReviewJournal of molecular histology2024

Alpha T-catenin: a crucial tumor suppressor in cancer pathogenesis.

Asma Boudouaia-Ouali, Majda Dali-Sahi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of molecular histology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Asma Boudouaia-OualiDepartment of Biology, University of Tlemcen, 13000, Tlemcen, Algeria. soma_1308@yahoo.fr.ORCID https://orcid.org/0000-0002-5059-0964
Majda Dali-SahiDepartment of Biology, University of Tlemcen, 13000, Tlemcen, Algeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alpha T-catenin has recently been identified as a crucial tumor suppressor in various cancer types, with roles that go beyond just providing structural support in adherens junctions. This review brings together recent findings on alpha T-catenin's important involvement in key signaling pathways related to cancer progression. We present strong evidence of its regulatory role in Wnt signaling, a pathway often disrupted in colorectal cancer, and explain how it inhibits cell proliferation and tumor growth. We also discuss the significant downregulation of alpha T-catenin in colorectal cancers and its potential as a prognostic marker. Moreover, this review looks at how increasing alpha T-catenin levels can reduce tumor growth and spread, suggesting new therapeutic strategies. Additionally, we reveal alpha T-catenin's unexpected impact on NF-κB signaling in basal E-cadherin-negative breast cancer, expanding its importance across different cancer types. By bringing these findings together, we provide a thorough understanding of alpha T-catenin's tumor-suppressing actions, setting the stage for new targeted therapies and diagnostic tools in cancer treatment.

Indexed as

alpha CateninNeoplasmsWnt Signaling PathwayAnimalsCell ProliferationGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansNF-kappa BSignal TransductionTumor Suppressor Proteinsalpha CateninNF-kappa BTumor Suppressor ProteinsAlpha T-cateninCellular adhesionE-cadherinNF-kB pathwayTumor suppressor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.